Table 1.
Basic characteristics of the included studies.
| Studies | Sample size (I/C) | Age(I/C) | Proteinuria (g/24 h) (I/C) | Scr (μmol/L) (I/C) | Intervention group | Control group | Treatment duration | Outcome |
|---|---|---|---|---|---|---|---|---|
| [14] | 30/30 | (32.8 ± 12.70)/(34.5 ± 11.7) | (1.48 ± 0.51)/(1.35 ± 0.63) | (87.4 ± 26.6)/(86.4 ± 25.4) | A manihot (2.5 g tid) plus olmesartan (20 mg/d) | Olmesartan (20 mg/d) | 12w | 24hUTP scr BUN ALB fib |
| [15] | 28/25 | (39.9 ± 7.9)/(41.7 ± 8.7) | (0.80 ± 0.38)/(0.78 ± 0.21) | — | A manihot(2.0 g tid) plus valsartan(80 mg/d) | Valsartan (80 mg/d) | 12w | 24hUTP eGFR SBP DBP |
| [16] | 24/24 | (34.4 ± 7.9)/(34.2 ± 8.1) | (1.85 ± 0.77)/(1.92 ± 0.66) | — | A manihot (2.5 g tid) plus irbesartan(150 mg/d) | Irbesartan (150 mg/d) | 12w | 24hUTP eGFR ALB SBP DBP |
| [17] | 70/60 | (30.2 ± 16.2)/(31.3 ± 15.4) | (2.72 ± 0.78)/(2.78 ± 0.63) | (181.62 ± 22.11)/(177.60 ± 19.13) | A manihot (2.5 g tid) plus lisinopril (10 mg bid) | Lisinopril (10g bid) | 8w | 24hUTP scr ALB CHO |
| [18] | 34/34 | (37.5 ± 3.6)/(37.2 ± 3.2) | (1.9 ± 0.8)/(1.8 ± 0.7) | — | A manihot (2.5 g tid) plus Irbesartan(150 mg/d) | Irbesartan (150 mg/d) | 12w | 24hUTP eGFR SBP DBP ALB |
| [19] | 42/38 | (36.4 ± 10.8)/(35.8 ± 12.4) | (1.8 ± 0.4)/(1.9 ± 0.3) | — | A manihot (2.5 g tid) plus benazepril (10 mg/d) | benazepril (10 mg/d) | 16w | 24hUTP RBC |
| [20] | 30/30 | — | (1.27 ± 0.73)/(0.94 ± 0.43) | (90.83 ± 15.43)/(89.23 ± 16.18) | A manihot (2.5 g tid) plus losartan(50 mg/d) | Losartan (50 mg/d) | 8w | 24hUTP scr BUN ALB |
| [11] | 72/76 | (37.2 ± 10.9)/(35.5 ± 11.0) | (1.02 ± 0.43)/(1.02 ± 0.44) | (73.26 ± 21.22)/(73.26 ± 18.56) | A manihot (2.5 g tid)plus losartan potassium (50 mg/d) | Losartan potassium (50 mg/d) | 24w | 24hUTP scr eGFR |
| [21] | 36/36 | — | (1.36 ± 0.64)/(1.38 ± 0.59) | (86.54 ± 26.35)/(86.60 ± 25.87) | A manihot (2.5 g tid) plus telmisartan(40 mg/d) | Telmisartan (40 mg/d) | 8w | 24hUTP scr BUN ALB fib |
| [22] | 20/39 | (34.0 ± 9.0)/(33.0 ± 8.0) | (2.91 ± 0.39)/(2.87 ± 0.37) | (114 ± 23)/(117 ± 24) | A manihot (2.5 g tid) plus benazepril(10 mg/d) | Benazepril (10 mg/d) | 8w | 24hUTP scr BUN MCP-1 |
| [23] | 26/26 | (37.1 ± 11.7)/(38.7 ± 12.1) | — | — | A manihot(2.5 g tid) plus losartan potassium(100 mg/d) | Losartan Potassium (100 mg/d) | 24w | 24hUTP scr ALB eEGFR |
I/C: intervention group/conventional group; Scr: serum creatinine; Bun: urea nitrogen; ALB: blood Albumin; Fib: fibrin; eGFR: estimated glomerular filtration rate; SBP: systolic blood pressure; DBP: Diastolic blood pressure; CHO: cholesterol; RBC: red blood cell; and MCP-1: human macrophage chemoattractant protein-1.